



Sosei Acquires Development and Commercialization Rights to Loramyc[®] from BioAlliance Pharma

Tokyo, Japan – 11 May 2011: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc[®] (miconazole Lauriad[®]. Sosei development code: SO-1105) in Japan from BioAlliance Pharma.

Loramyc[®] is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. BioAlliance received its first Loramyc[®] marketing authorization in France in October 2006. Loramyc[®] has since been registered in 26 European countries, in South Korea, and in the United States.

Under the terms of the agreement, Sosei will pay BioAlliance an upfront license fee of \$3 million and further development and sales-based milestones totaling up to a maximum of \$18.5 million. Sosei will also pay royalties on net sales of the product.

By acquiring development and commercialization rights to Loramyc[®] Sosei will broaden its development pipeline and continue with its strategy of bringing products that are in the late stage of development or already marketed in the West to Japan.

Shinichi Tamura, CEO of Sosei Group Corporation, commented: "We are very pleased to be teaming up with BioAlliance Pharma on this innovative product. Loramyc[®] has the potential to become the first treatment in tablet form for oropharyngeal candidiasis in Japan, to provide an important addition to available treatments, and to enhance patients' compliance and improve their quality of life."

- Ends -

Enquiries:

Sosei Group Corporation	
Tokyo Office	London Office
Milica STOJKOVIC Investor Relations	Kathryn LYDON, PA to CEO & Corporate Communication
+81-(0)3-5210-3399	+44-(0)20-7691-0983
mstojkovic@sosei.com	KLydons@sosei.com

Notes for Editors:

About Oropharyngeal Candidiasis

Fungal infections of the oral mucosa are most frequently caused by *Candida* species, with *C. albicans* being the most common species associated with such infections. Oropharyngeal candidiasis is commonly found in immuno-compromised patients, including HIV and cancer patients, and in other chronic disease states such as diabetes. For instance, oropharyngeal candidiasis is the most frequently occurring infection in head and neck cancer patients undergoing radiation therapy. The clinical presentation of oropharyngeal candidiasis is variable with symptoms including soreness, burning, and/or altered taste. The signs of clinical candidiasis usually include white pseudomembraneous plaques and patches (thrush), erythematous lesions or occasionally angular cheilitis. Left untreated, the condition may progress to involve the esophagus or to more serious systemic complications.

About Sosei

Sosei is an international biopharmaceutical company anchored in Japan with a global reach. It practises a reduced risk business model by acquiring compounds from, and bringing compounds into, Japan through exploitation of its unique position within global markets.

For further information about Sosei, please visit www.osei.com.

About BioAlliance Pharma

Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and radiotherapy-induced complications and opportunistic infections in immunocompromised patients – BioAlliance conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products' commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:

Loramyc[®]/Oravig[®] (oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries, in Korea and in the United States

Setofilm[®] (prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries

Sitavir[™] (Acyclovir Lauriad[™]) (labialis herpes): Positive phase III final results; registration status

Fentanyl Lauriad[™] (chronic cancer pain): Positive preliminary Phase I results

AMEP[®] (invasive melanoma): Phase I

Clonidine Lauriad[™] (mucositis): Phase II

Doxorubicin Transdrug[®] (liver cancer): Phase II

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com